Stock comparison
Artivion
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AORT
Artivion
Market cap
$1.09B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AORT | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 35D | 71B | UTHR |
| Benjamin Graham | 63D | 76B | UTHR |
| Philip Fisher | 48D | 76B | UTHR |
| Peter Lynch | 32F | 62C | UTHR |
| Joel Greenblatt | 41D | 46D | UTHR |
| Charlie Munger | 43D | 64C | UTHR |
| Terry Smith | 36D | 64C | UTHR |
Side-by-side metrics
| Metric | AORT | UTHR |
|---|---|---|
| Market cap | $1.09B | $24.13B |
| P/E (TTM) | 93.6x | 19.2x |
| EV/EBIT | 48.9x | 15.2x |
| ROIC (TTM) | 3.0% | 18.81% |
| Gross margin | 62.94% | 86.58% |
| Net margin | 2.55% | 40.61% |
| Revenue CAGR 5y | 10.24% | 17.22% |
| EPS CAGR 5y | - | 29.84% |
| Debt / Equity | 0.6x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AORT leads on
No clear edges - the other side wins or ties on every measured metric.
UTHR leads on
- Debt / Equity-vs 0.6x+100%
- Market cap$24.13Bvs $1.09B+95%
- Net margin40.61%vs 2.55%+94%
- ROIC (TTM)18.81%vs 3.0%+84%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.